共 50 条
T regulatory cells, the evolution of targeted immunotherapy
被引:34
|作者:
Nizar, S.
[1
,2
]
Meyer, B.
[1
]
Galustian, C.
[1
]
Kumar, D.
[2
]
Dalgleish, A.
[1
]
机构:
[1] St Georges Univ London, Dept Cellular & Mol Med, London SW17 0RE, England
[2] St Georges Hosp NHS Trust, Dept Colorectal Surg, London, England
来源:
关键词:
T regulatory;
Tregs;
FOXP3;
Cancer;
Immunotherapy;
PHASE-II TRIAL;
DENILEUKIN DIFTITOX;
DENDRITIC CELLS;
ANTITUMOR IMMUNITY;
CTLA-4;
BLOCKADE;
TGF-BETA;
PERIPHERAL-BLOOD;
PROSTATE-CANCER;
FUSION PROTEIN;
IN-VITRO;
D O I:
10.1016/j.bbcan.2010.02.001
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
T regulatory cells are able to suppress anti-tumour immunity in pre-clinical models and in patients. This review highlights the important discoveries in Treg immunology critical to the evolution of targeted immunotherapy. We also describe the therapeutic applications that are currently being assessed and their future potential. (C) 2010 Elsevier BM. All rights reserved.
引用
收藏
页码:7 / 17
页数:11
相关论文